{
    "Case ID": "091396",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent infringement dispute"
    ],
    "Legal_Issue": [
        "Whether Novopharm's supplier's process for producing fluoxetine hydrochloride infringes Lilly's patent"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Procedural_Stage": [
        "Judicial review under s. 6(1) of the Regulations"
    ],
    "Evidence_Assessment": [
        "Evaluation of expert evidence from both parties on chemical processes"
    ],
    "Decision_Outcome": [
        "Prohibition order granted in favor of Lilly"
    ],
    "Burden_of_Proof": [
        "On Novopharm to justify non-infringement allegations"
    ],
    "Credibility_Factor": [
        "Expert testimony credibility assessed by court"
    ],
    "Legal_Rule": [
        "Obvious chemical equivalents constitute infringement under the Regulations"
    ],
    "Standard_of_Review": [
        "Reasonableness or correctness, as applicable to regulatory interpretation"
    ],
    "Procedural_Issue": [
        "Application for prohibition under regulatory framework"
    ],
    "Grounds_for_Claim": [
        "Allegation that Fermion process uses non-infringing method"
    ],
    "Outcome_on_Merits": [
        "Claim dismissed; infringement found due to obvious chemical equivalents"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "Lilly's application granted"
    ],
    "Review_Standard": [
        "Interpretation of regulatory provisions and factual assessment"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing provided with opportunity to present expert evidence"
    ],
    "Key_Evidence_Considered": [
        "Differences in protecting groups and reaction steps in chemical synthesis"
    ],
    "Legal_Framework": [
        "Regulatory regime for patented medicines and market approval"
    ],
    "Applicant_Challenge": [
        "Lilly challenged Novopharm's allegation of non-infringement"
    ],
    "Court_Result": [
        "Prohibition order issued; Novopharm cannot receive Notice of Compliance until patent expiry"
    ],
    "Legal_Rule_Source": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Novopharm alleged its supplier’s process did not infringe Lilly’s patent"
    ],
    "Evidence_Type": [
        "Scientific and technical expert evidence"
    ],
    "Remedy_Requested": [
        "Prohibition against issuance of Notice of Compliance to Novopharm"
    ],
    "Outcome": [
        "Remedy granted"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Prevention of market entry until patent expiration"
    ],
    "Resolution_Mechanism": [
        "Judicial review and regulatory compliance determination"
    ],
    "Legal_Provision": [
        "Section 6(1) of the Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Authority": [
        "Minister of Health, subject to court direction"
    ],
    "Claimant_Status": [
        "Patent holder (Lilly)"
    ],
    "Legal_Provision_Cited": [
        "s. 6(1) of the Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Infringement via obvious chemical equivalents"
    ],
    "Applicable_Process": [
        "Regulatory approval process for generic drugs"
    ],
    "Outcome_of_Review": [
        "Prohibition upheld"
    ],
    "Pending_Relief_or_Application": [
        "Application for Notice of Compliance by Novopharm"
    ],
    "Jurisdiction": [
        "Federal jurisdiction, Canada"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ]
}